Orelabrutinib

Orelabrutinib is a drug for the treatment of cancer.

In China, it is approved for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), who have received at least one treatment in the past.

Orelabrutinib is an inhibitor of Bruton's tyrosine kinase.